Howard Burris, MD, FASCO from the Sarah Cannon Research Institute, Nashville, TN, discusses the ICONIC trial, a Phase I/II study of JTX-2011, a monoclonal antibody targeting ICOS, developed by Jounce Therapeutics, alone or in combination with nivolumab in patients with advanced solid tumors (NCT02904226). He states that the current results for the trial appear promising and that patients receiving the combination regimen are still receiving therapy and are responding well. This interview was filmed at the American Society of Oncology (ASCO) 2017 Annual Meeting in Chicago, IL.
